These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 9797415)

  • 41. In vitro activity of cefditoren and other comparators against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis causing community-acquired respiratory tract infections in China.
    Yang Q; Xu Y; Chen M; Wang H; Sun H; Hu Y; Zhang R; Duan Q; Zhuo C; Cao B; Liu Y; Yu Y; Sun Z; Chu Y
    Diagn Microbiol Infect Dis; 2012 Jun; 73(2):187-91. PubMed ID: 22521692
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Parameters characterizing the in vitro activity of cefixime, a new oral broad spectrum cephalosporin, against respiratory and urinary pathogens.
    Debbia EA; Marchese A; Pesce A; Saverino D; Schito GC
    J Chemother; 1992 Jun; 4(3):131-44. PubMed ID: 1517806
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Clinical studies of cefixime granules in pediatrics].
    Nakazawa S; Sato H; Narita A; Nakazawa S; Suzuki H; Matsumoto K; Chikaoka H; Kamigaki M; Koido R; Niino K
    Jpn J Antibiot; 1986 Apr; 39(4):1020-34. PubMed ID: 3761535
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The role of newer oral cephalosporins, fluoroquinolones, and macrolides in the treatment of pediatric infections.
    Rodriguez WJ; Wiedermann BL
    Adv Pediatr Infect Dis; 1994; 9():125-59. PubMed ID: 8123221
    [No Abstract]   [Full Text] [Related]  

  • 45. [Fundamental and clinical studies on cefixime (5% granules) in the pediatric field].
    Toyonaga Y; Sugita M; Nakamura H; Joh K; Takahashi T; Kurosu Y; Hori M
    Jpn J Antibiot; 1986 Apr; 39(4):1055-75. PubMed ID: 3761537
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Review and reassessment of dosing schedules for cefotaxime in selected medical indications.
    Young LS
    Diagn Microbiol Infect Dis; 1995; 22(1-2):147-54. PubMed ID: 7587030
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Fundamental and clinical studies on cefixime in pediatrics].
    Iwai N; Shibata M; Mizoguchi F; Nakamura H; Katayama M
    Jpn J Antibiot; 1986 Apr; 39(4):1087-105. PubMed ID: 3761539
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Comparative antibacterial activity of cefpodoxime against Haemophilus influenzae, Streptococcus pyogenes, Streptococcus pneumoniae and Moraxella catarrhalis].
    Wallrauch-Schwarz C; Milatovic D; Braveny I
    Arzneimittelforschung; 1994 May; 44(5):668-70. PubMed ID: 8024645
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy of ceftibuten for acute otitis media caused by Hemophilus influenzae: an animal study.
    Rosenfeld RM; Doyle WJ; Swarts JD; Seroky J; Greene I
    Ann Otol Rhinol Laryngol; 1993 Mar; 102(3 Pt 1):222-6. PubMed ID: 8457124
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Antibacterial effect of cefixime].
    Soussy CJ; Meyran M; Duval J
    Presse Med; 1989 Oct; 18(32):1546-50. PubMed ID: 2530528
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Third-generation cephalosporins: a critical evaluation.
    Barriere SL; Flaherty JF
    Clin Pharm; 1984; 3(4):351-73. PubMed ID: 6432420
    [TBL] [Abstract][Full Text] [Related]  

  • 52. In vitro activity and clinical evaluation of cefixime in urinary tract infection.
    Asvanich K; Fugpholngam V; Srimuang S; Tanphaichitra D
    J Med Assoc Thai; 1998 Apr; 81(4):301-4. PubMed ID: 9623027
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Bacteriologic and clinical efficacy of cefixime compared with amoxicillin in acute otitis media.
    Howie VM; Owen MJ
    Pediatr Infect Dis J; 1987 Oct; 6(10):989-91. PubMed ID: 3696839
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [A randomized controlled clinical study of cefetamet pivoxil versus cefixime in the treatment of 99 cases bacterial infections].
    Zhao C; Li J; Hao F
    Zhonghua Nei Ke Za Zhi; 1997 Jul; 36(7):465-8. PubMed ID: 10436948
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cefotaxime. A reappraisal of its antibacterial activity and pharmacokinetic properties, and a review of its therapeutic efficacy when administered twice daily for the treatment of mild to moderate infections.
    Brogden RN; Spencer CM
    Drugs; 1997 Mar; 53(3):483-510. PubMed ID: 9074846
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evaluation of cefixime in the treatment of bacterial maxillary sinusitis.
    Matthews BL; Kohut RI; Edelstein DR; Rybak LP; Rapp M; McCaffrey TV; Kimmelman CP; Parnes SM; Marinaccio AT; Kohlbrenner VM
    South Med J; 1993 Mar; 86(3):329-33. PubMed ID: 8451674
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cefixime, in-vitro activity, pharmacokinetics and tissue penetration.
    Stone JW; Linong G; Andrews JM; Wise R
    J Antimicrob Chemother; 1989 Feb; 23(2):221-8. PubMed ID: 2708180
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A critical review of the new oral cephalosporins. Considerations and place in therapy.
    Rodman DP; McKnight JT; Anderson RL
    Arch Fam Med; 1994 Nov; 3(11):975-80. PubMed ID: 7804480
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Penetration and bactericidal activity of cefixime in synovial fluid.
    Somekh E; Heifetz L; Dan M; Poch F; Hafeli H; Tanai A
    Antimicrob Agents Chemother; 1996 May; 40(5):1198-200. PubMed ID: 8723466
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Effects of cefixime and cefaclor on pharyngeal flora in children].
    Sakata H; Maruyama S
    Kansenshogaku Zasshi; 1991 May; 65(5):546-51. PubMed ID: 1880444
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.